SGLT2 Inhibitors Linked to Better Outcomes in Diabetes and Cirrhosis - Poll - MDSpire

SGLT2 Inhibitors Linked to Better Outcomes in Diabetes and Cirrhosis

A nationwide cohort study found lower rates of cardiorenal complications and hepatic decompensation

  • By

  • Henry Thomas

  • March 10, 2026

  • 2 min

Share

Original Source(s)

SGLT2 Inhibitors Linked to Better Outcomes in Diabetes and Cirrhosis

  • by Henry Thomas

  • March 10, 2026

Related Content

FDA Expands Afrezza to Pediatric Diabetes

The decision was supported by the phase 3 INHALE-1 trial and additional long-term safety, efficacy, and exposure data.

Mapping the gut microbiota-diabetic peripheral neuropathy research landscape: a bibliometric analysis of emerging trends and translational frontiers

Retinal Age as Disease Biomarker

Fundus-based AI screening can indicate “retinal age” of patients, as well as flag systemic disease risks, says new study

  • May 27, 2026

  • 3 min